Literature DB >> 15447983

Hypermethylation in histologically distinct classes of breast cancer.

Young Kyung Bae1, Amy Brown, Elizabeth Garrett, Daniel Bornman, Mary Jo Fackler, Saraswati Sukumar, James G Herman, Edward Gabrielson.   

Abstract

PURPOSE: A number of different genes are known to be inactivated by aberrant hypermethylation in breast cancer, but it is still unknown to what extent these epigenetic alterations differ according to specific breast cancer phenotypes. We sought to determine whether the extent of hypermethylation or defined profiles of gene hypermethylation are associated with biological characteristics of breast cancers. EXPERIMENTAL
DESIGN: We evaluated methylation status of 12 different genes in a series of 109 invasive breast tumors, representing the ductal, lobular, and mucinous histologic subtypes using methylation-specific PCR. Frequencies of methylation were compared across the recognized histologic classes, and multivariate techniques (latent class analysis, factor analysis, recursive partitioning, and hierarchical clustering) were used to seek patterns of methylation for individual genes that distinguish recognized histologic types of breast cancer or define breast cancer phenotypes on a molecular level.
RESULTS: All 109 cases studied have aberrant methylation of multiple genes (3 to 10 genes per case), demonstrating that gene hypermethylation is pervasive in breast cancer. Lobular cancers and mucinous cancers, which often have relatively low levels of chromosomal changes, have higher overall frequencies of hypermethylation than ductal cancers (49% in lobular and mucinous versus 40% in ductal), but there is a relatively unimodal distribution of methylation frequency for all three histologic types. Only one of the individual genes studied, BRCA1, has a variable frequency of methylation that is significantly dependent on histologic pattern of tumor growth, with a higher frequency of methylation in mucinous cancers than ductal or lobular cancers. Although some trends of histology-specific gene methylation were seen, methylation patterns could not definitively classify breast cancers according to histologic type.
CONCLUSIONS: Although a more comprehensive hypermethylation profile could potentially be useful for breast cancer classification and understanding the biology of this disease, it appears that the hypermethylation patterns across various forms of breast cancer are less distinct than those between breast cancer and cancers of different tissue origins. Furthermore, the relatively unimodal distribution of methylation frequency for all three histologic types does not support there being a distinct CpG island methylator phenotype for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15447983     DOI: 10.1158/1078-0432.CCR-04-0667

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

Review 1.  The epigenetics of breast cancer.

Authors:  Jovana Jovanovic; Jo Anders Rønneberg; Jörg Tost; Vessela Kristensen
Journal:  Mol Oncol       Date:  2010-04-29       Impact factor: 6.603

2.  Basal-like breast cancer displays distinct patterns of promoter methylation.

Authors:  Ji Shin Lee; Mary Jo Fackler; Jae Hyuk Lee; Chan Choi; Min Ho Park; Jung Han Yoon; Zhe Zhang; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2010-06-18       Impact factor: 4.742

Review 3.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

Authors:  Ashley G Rivenbark; Siobhan M O'Connor; William B Coleman
Journal:  Am J Pathol       Date:  2013-08-27       Impact factor: 4.307

4.  Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues.

Authors:  Dimo Dietrich; Ralf Lesche; Reimo Tetzner; Manuel Krispin; Jörn Dietrich; Wolfgang Haedicke; Matthias Schuster; Glen Kristiansen
Journal:  J Histochem Cytochem       Date:  2009-01-19       Impact factor: 2.479

5.  Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.

Authors:  Asia Asiaf; Shiekh Tanveer Ahmad; Ajaz Ahmad Malik; Shiekh Aejaz Aziz; Zubaida Rasool; Akbar Masood; Mohammad Afzal Zargar
Journal:  Tumour Biol       Date:  2015-03-29

6.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Gene promoter hypermethylation in tumors and plasma of breast cancer patients.

Authors:  Young Kyung Bae; Young Ran Shim; Joon Hyuk Choi; Mi Jin Kim; Edward Gabrielson; Soo Jung Lee; Tae Yoon Hwang; Sei One Shin
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

8.  Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.

Authors:  Mercedes Zurita; Pedro C Lara; Rosario del Moral; Blanca Torres; José Luis Linares-Fernández; Sandra Ríos Arrabal; Joaquina Martínez-Galán; Francisco Javier Oliver; José Mariano Ruiz de Almodóvar
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

9.  Array-based DNA methylation profiling for breast cancer subtype discrimination.

Authors:  Ilse Van der Auwera; Wayne Yu; Liping Suo; Leander Van Neste; Peter van Dam; Eric A Van Marck; Patrick Pauwels; Peter B Vermeulen; Luc Y Dirix; Steven J Van Laere
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

10.  Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.

Authors:  Sondes Karray-Chouayekh; Fatma Trifa; Abdelmajid Khabir; Nouredine Boujelbane; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  J Biomed Biotechnol       Date:  2009-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.